# GlaxoSmithKline

> GlaxoSmithKline is a VC fund in London backing Biotechnology and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: London, United Kingdom
- Total investments: 16
- Last investment: Aug 2026
- Lead investor: 44%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/glaxosmithkline
- X (Twitter): http://twitter.com/gsk
- Website: http://www.gsk.com
- Facebook: http://www.facebook.com/GSK

GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people. GSK'sPharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies.The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries.The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.

## Contacts

5 contacts available for GlaxoSmithKline. Shizune tracks 13 team members at GlaxoSmithKline. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/glaxosmithkline?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 13 | 81% |
| Health Care | 9 | 56% |
| Therapeutics | 8 | 50% |
| Medical | 4 | 25% |
| Medical Device | 3 | 19% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 31% |
| Series B | 3 | 19% |
| Post-IPO Equity | 3 | 19% |
| Series C | 2 | 13% |
| Grant | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 11 | 69% |
| United Kingdom | 2 | 13% |
| Canada | 1 | 6% |
| Switzerland | 1 | 6% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Karenann Terrell | Chief Digital and Technology officer | 1 | https://shizune.co/investors/profile/karenann-terrell |
| Nick Tate | VP Digital Innovation | 12 | https://shizune.co/investors/profile/nick-tate |
| Brian McNamara | CEO GSK Consumer Healthcare | 0 | https://shizune.co/investors/profile/brian-mcnamara-51ce |
| Carol Gallagher | Member, Discovery Investment Board | 7 | https://shizune.co/investors/profile/carol-gallagher |
| Emma Walmsley | CEO | 0 | https://shizune.co/investors/profile/emma-walmsley |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $188M | Series E | Aug 06, 2026 |  |
| Asceneuron | Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression. | $100M | Series C | Jul 16, 2024 |  |
| Canadian Centre for Vaccinology | Canadian Centre for Vaccinology is an integrated collaborative interdisciplinary vaccine research team committed to excellent research. | $1M | Grant | May 31, 2023 |  |
| Wave Life Sciences | WaVe Life Sciences is leading a revolution in nucleic acid therapeutics and was founded on the core principle that medicines should possess precisely controlled molecular structures. We and our strategic partners are advancing a portfolio of stereopure drug candidates that target underlying biology across a wide range of human diseases.WaVemaintains R&D facilities in Boston and Japan and was founded by two world-renowned scientific leaders, Gregory Verdine and Takeshi Wada. Dr. Verdine is an Erving Professor of Chemistry in the Harvard University Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology. Dr. Wada is a professor at Tokyo University of Science, Faculty of Pharmaceutical Sciences and Department of Medicinal and Life Science. | $50M | Post-IPO Equity | Dec 13, 2022 |  |
| Spero Therapeutics | Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterialinfections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens. | $9M | Post-IPO Equity | Sep 22, 2022 |  |
| LifeMine Therapeutics | Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $175M | Series C | Mar 23, 2022 |  |
| Adrestia Therapeutics | Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells | $232.6M | Series A | Dec 18, 2020 |  |
| Vir Biotechnology | Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™protease-releasable masking technology in infectious diseases and cancer, respectively.We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola.Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients. | $250M | Post-IPO Equity | Apr 07, 2020 |  |
| SpringWorks Therapeutics | SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.The company was founded in 2017 and headquartered inConnecticut, United States. | $125M | Series B | Apr 01, 2019 |  |
| Atreca | Atreca is a biopharmaceutical that develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen. Its product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target-derived from an antibody identified using its discoveryplatform. | $56M | Series A | Nov 04, 2015 |  |

10 of 16 investments shown.

## Co-investors
- [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures) — VC Fund, 3 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 2 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does GlaxoSmithKline invest in?

GlaxoSmithKline invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact GlaxoSmithKline?

Public channels for GlaxoSmithKline include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at GlaxoSmithKline?

The team at GlaxoSmithKline includes Karenann Terrell (Chief Digital and Technology officer), Nick Tate (VP Digital Innovation) and Brian McNamara (CEO GSK Consumer Healthcare), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co